Evaluation of AFP for diagnosis of HCC in Egyptian patients | ||
| Journal of Medical and Life Science | ||
| Volume 5, Issue 1, March 2023, Pages 43-48 PDF (1.2 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jmals.2023.329306 | ||
| Authors | ||
| Ahmed Abdelhalim Yameny* 1; Sabah Farouk Alabd1; Magda Ahmed M. Mansor2 | ||
| 1Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt | ||
| 2Department of Histology, Faculty of Medicine, Menoufia University, Egypt | ||
| Abstract | ||
| Background: It was initially suggested in the 1960s to use AFP as a tumor marker for hepatocellular carcinoma (HCC), AFP still plays a big part in HCC monitoring. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients were divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: there was a statistically significant difference between the five groups p-value >0.001*, compared to the control group the three groups G2, G3, and G5 have the same statistically significant difference with the same p-value >0.001*, while group 4 HBV patients have not statistically significant difference with p-value 0.254 compared to the control group, Serum AFP highly significant elevated in HCC patients associated with HCV or HBV infection patients. | ||
| Keywords | ||
| Alpha-fetoprotein; AFP; HBV; HCV; HCC; Liver diseases | ||
|
Statistics Article View: 151 PDF Download: 335 |
||
